Chemomab Therapeutics Management
Management criteria checks 3/4
Chemomab Therapeutics' CEO is Adi George, appointed in Jan 2011, has a tenure of 13.33 years. total yearly compensation is $330.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4% of the company’s shares, worth $477.87K. The average tenure of the management team and the board of directors is 1.2 years and 3.2 years respectively.
Key information
Adi George
Chief executive officer
US$330.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 13.3yrs |
| CEO ownership | 4.0% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$330k | US$330k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$435k | US$298k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$16m |
| Dec 31 2021 | US$488k | US$249k | -US$12m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | US$325k | US$229k | -US$6m |
Compensation vs Market: Adi's total compensation ($USD330.00K) is below average for companies of similar size in the US market ($USD661.15K).
Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.
CEO
Adi George (41 yo)
13.3yrs
Tenure
US$330,000
Compensation
Dr. Adi Mor George, Ph.D. serves as Chief Executive Officer of Chemomab Therapeutics Ltd. since June 01, 2023. She is the Co-Founder of Chemomab Therapeutics Ltd.and has been its Chief Scientific Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.3yrs | US$330.00k | 4% $ 477.9k | |
| Chief Financial Officer | less than a year | US$322.00k | 0.11% $ 12.6k | |
| Chief Medical Officer & VP of Drug Development | 1.5yrs | US$850.00k | 0% $ 0 | |
| Consulting Vice President of Investor & Public Relations | no data | no data | no data | |
| Senior VP of Global Clinical Development Operations | less than a year | no data | no data |
1.2yrs
Average Tenure
52yo
Average Age
Experienced Management: CMMB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.2yrs | US$330.00k | 4% $ 477.9k | |
| Independent Director | 4.1yrs | US$123.00k | 1.06% $ 127.2k | |
| Independent Chairman | 3.2yrs | US$123.00k | 0.0084% $ 1.0k | |
| Independent Director | 3.2yrs | US$119.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.2yrs | US$123.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.9yrs | US$38.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.2yrs
Average Tenure
58.5yo
Average Age
Experienced Board: CMMB's board of directors are considered experienced (3.2 years average tenure).